Seres Therapeutics (MCRB) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 4, 2022 7:00 AM EDTSER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022
FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track for mid-2022
SER-109 pre-commercialization activities underway, including medical education and payer engagement
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS... More
